Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. ($TNDM) is a medical device company specializing in diabetes management solutions. The stock had a bearish movement today in the market.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.1% on Feb 27, 2026 19:46

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Envestnet Asset Management Inc. Cuts Stock Position in Tandem Diabetes Care, Inc. $TNDM

Envestnet Asset Management Inc. has reduced its stake in Tandem Diabetes Care, Inc. by 15% in the third quarter, selling 41,678 shares and now holding 236,332 shares valued at approximately $2.87 million. Despite beating quarterly EPS and revenue estimates, the medical device company remains unprofitable. Analysts currently have a "Hold" rating on Tandem Diabetes Care with a consensus target price of $28.00.

https://www.marketbeat.com/instant-alerts/filing-envestnet-asset-management-inc-cuts-stock-position-in-tandem-diabetes-care-inc-tndm-2026-02-26/

Is It Time To Reassess Tandem Diabetes Care (TNDM) After The Recent 43% Price Jump

Tandem Diabetes Care (TNDM) has seen a significant 43% price jump recently, sparking interest in its valuation despite a decline over the past year and five years. A Discounted Cash Flow (DCF) analysis suggests the stock is currently around 6.7% overvalued at US$26.90, while a Price-to-Sales (P/S) ratio analysis indicates it might be undervalued. The article also presents "Narratives" for investors to consider, offering both bull and bear case valuations based on different growth assumptions and risk factors.

https://simplywall.st/stocks/us/healthcare/nasdaq-tndm/tandem-diabetes-care/news/is-it-time-to-reassess-tandem-diabetes-care-tndm-after-the-r

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

Tandem Diabetes Care announced the pricing of an upsized private placement of $265 million in 0.00% Convertible Senior Notes due 2032. The net proceeds are estimated to be $256.7 million, or up to $290.7 million if an option for additional notes is exercised, and will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will not bear regular interest, mature on March 15, 2032, and have an initial conversion price of approximately $36.99 per share, representing a 37.5% premium over Tandem's common stock's last reported sale price.

https://finance.yahoo.com/news/tandem-diabetes-care-prices-upsized-053000110.html

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

Tandem Diabetes Care, Inc. announced the pricing of an upsized private placement of $265.0 million in 0.00% Convertible Senior Notes due 2032. The net proceeds of approximately $256.7 million will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will mature on March 15, 2032, and are convertible into cash, common stock, or a combination thereof, at the company's election, with an initial conversion price of approximately $36.99 per share.

https://aijourn.com/tandem-diabetes-care-prices-upsized-private-placement-of-265-million-of-convertible-senior-notes-due-2032/

Tandem Diabetes Care (TNDM) Price Target Increased by 19.37% to 29.72

The average one-year price target for Tandem Diabetes Care (TNDM) has increased by 19.37% to $29.72 per share, up from $24.90. This new target represents a 10.48% increase from the last closing price of $26.90. Institutional ownership shows a slight decrease in the number of funds holding positions but a bullish outlook with a put/call ratio of 0.42.

https://www.nasdaq.com/articles/tandem-diabetes-care-tndm-price-target-increased-1937-2972

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.7% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Vornado Realty Trust ($VNO) Stock Forecast: Down 5.7% Today

Boston Properties Inc. ($BXP) Stock Forecast: Down 5.5% Today

PNC Financial Services Group Inc. (The) ($PNC) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 5.6% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.0% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 5.8% Today

Netflix Inc. ($NFLX) Stock Forecast: Up 13.9% Today

Tandem Diabetes Care, Inc. Price History

24.01.2026 - TNDM Stock was up 5.3%

• Tandem Diabetes Care's bullish movement today could be attributed to the positive market reception of its proposed private placement of convertible notes, signaling investor confidence in the company's growth prospects.
• The upgrade of Tandem Diabetes Care's stock rating by Lake Street Capital Markets, driven by the successful transition to a pharmacy distribution model, likely contributed to the bullish sentiment surrounding the company.
• The projected significant growth of the global insulin delivery devices market, with insulin pumps expected to dominate the market share, could have also positively influenced Tandem Diabetes Care's stock performance as a key player in this industry.
• Overall, the combination of strategic financial moves, positive analyst outlook, and favorable market trends in the healthcare sector likely fueled Tandem Diabetes Care's strong bullish movement today.

20.01.2026 - TNDM Stock was up 31.3%

• Adjusting Tandem Diabetes Care's price target upwards and maintaining a Hold rating likely contributed to investor optimism and buying interest in the stock.
• Tandem Diabetes Care's record-setting Q4 and full-year 2025 financial performance, surpassing $1 billion in sales, and achieving double-digit growth with improved profitability, showcased the company's strong fundamentals and growth potential.
• The strategic shift towards a "pay-as-you-go" reimbursement structure in the U.S. pharmacy channel, despite near-term revenue headwinds, signals a long-term focus on market expansion and profitability, which could have positively influenced investor sentiment.
• The introduction of new technologies like Control-IQ+ and Mobi Tubeless, along with strong financial results and optimistic 2026 guidance, likely fueled investor confidence and contributed to the significant bullish movement in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 10.1%

• Tandem Diabetes Care's stock witnessed a surge of over 32% due to record margins and a revenue beat, supported by strong demand for its insulin pumps and enhanced gross margin.
• An upgrade by Lake Street Capital Markets to a Buy rating with a price target of $50.00 bolstered investor confidence, underscoring the company's successful shift to a pharmacy distribution model.
• The projected growth of the global insulin delivery devices market, particularly in insulin pumps leading the market share, also contributed to positive sentiment surrounding Tandem Diabetes Care.
• A combination of robust financial performance, margin expansion, and positive sales forecasts for 2026 resulted in a short squeeze and a notable increase in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 6.3%

• Tandem Diabetes Care (TNDM) saw a remarkable 33% surge in its stock performance today, propelled by exceptional margins and outperforming revenue figures, prompting a short squeeze and a notable price upswing.
• The company delivered robust results in the fourth quarter, driven by a strong demand for its insulin pumps and an enhanced gross margin, contributing to the significant rise in its stock value.
• With an innovative pay-as-you-go pharmacy model that is augmenting margin expansion and generating recurring revenue, Tandem Diabetes Care is well-positioned for sustained profitable growth in 2026, with anticipated sales ranging between $1.065 billion and $1.085 billion.
• Tandem Diabetes Care's strategic initiatives for future expansion, such as the emphasis on the "pay-as-you-go" approach and the projected increase in pump shipments for 2026, have elicited positive responses from investors and analysts, despite a slightly lower-than-expected sales forecast for the fiscal year 2026.

20.01.2026 - TNDM Stock was up 19.0%

• Tandem Diabetes Care outperformed revenue expectations in Q4 2025 with a 15% increase year-over-year and a GAAP EPS loss of $0.01, surpassing projections. This strong financial performance is believed to have fueled the stock's bullish movement.
• Despite providing cautious 2026 sales guidance due to challenges from new business models, investors are optimistic about the company's strategic repositioning and improved profitability forecasts for 2027 and beyond, resulting in an increase in the stock's value in after-hours trading.
• The company's robust Q4 results, which exceeded revenue and EPS forecasts, coupled with positive future profitability prospects, likely bolstered investor confidence and led to the stock's upward trajectory.
• Tandem Diabetes Care's ability to beat revenue expectations, enhance operating margin, and achieve over $1 billion in global sales for 2025 demonstrates its strength and growth potential, which probably attracted investors and contributed to the favorable market movement.

20.01.2026 - TNDM Stock was up 39.4%

• Following the release of its Q4 2025 earnings report, Tandem Diabetes Care (TNDM) saw a strong bullish movement, with record-setting sales surpassing $1 billion and double-digit growth.
• Positive market response was observed towards TNDM's enhanced profitability, operational improvements, and the launch of new technologies like Control-IQ+ and Mobi Tubeless, reflecting investor confidence in the company's strategic direction.
• Despite issuing cautious sales guidance for 2026 due to transitional challenges from new business models, investors displayed optimism in TNDM's potential long-term profitability, leading to a rise in the stock price during after-hours trading.
• TNDM's ability to surpass revenue projections, enhance operating margins, and anticipate ongoing sales growth, particularly with the introduction of new pay-as-you-go pharmacy structures, contributed to the optimistic sentiment surrounding the stock.

25.01.2026 - TNDM Stock was down 7.8%

• The disclosure of pricing and upsizing details of the private placement of convertible senior notes due in 2032 likely sparked investor worries about possible share dilution, contributing to the prevailing bearish sentiment.
• Despite the favorable development of a stock rating upgrade by Lake Street Capital Markets attributed to a successful transition to a pharmacy distribution model, the attention on the convertible notes offering appeared to overshadow the favorable shift in the company's business approach.
• Investors are possibly exercising caution regarding the company's intention to utilize the proceeds for potential acquisitions, raising uncertainties about future growth and profitability.
• Market response suggests that while the strategic shift's long-term advantages are acknowledged, immediate concerns regarding share dilution and capital deployment choices are exerting a negative influence on the stock's performance.

19.01.2026 - TNDM Stock was down 5.2%

• The recent decline in TNDM's stock is linked to the ongoing legal concerns and heightened scrutiny stemming from a shareholder lawsuit investigation concerning its t:slim X2 insulin pumps.
• Investor apprehension may be driven by the potential impact of this issue on the company's reputation, product reliability, patient confidence, and disclosure practices, potentially prompting a sell-off of the stock.
• While analysts had optimistic expectations for a narrower loss and increased revenue in the upcoming earnings announcement, uncertainties surrounding the legal inquiry and its financial consequences appear to have outweighed any positive projections, resulting in the downward trend in TNDM's market performance.

27.01.2026 - TNDM Stock was down 5.1%

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

03.01.2026 - TNDM Stock was down 7.0%

• TNDM faced a downward trend following the announcement of a voluntary medical device correction for its t:slim X2 insulin pumps.
• The correction addressed a possible speaker-related issue that could disrupt insulin delivery, sparking concerns about the product's reliability.
• A probe by the Rosen Law Firm into potential securities claims exacerbated the negative sentiment surrounding TNDM and led to a significant drop in the stock price.
• Investors reacted strongly to these developments, reflecting apprehensions about the potential impact on Tandem Diabetes Care's financial performance and reputation.

12.01.2026 - TNDM Stock was down 5.1%

• TNDM stock faced a bearish movement possibly linked to ongoing investigations related to potential securities claims by The Rosen Law Firm and a previous stock decline after a voluntary medical device correction announcement.
• The expected loss per share in the upcoming earnings report may have further dampened investor sentiment towards the stock.
• Investor concerns about the reliability and safety of Tandem's insulin pumps, as highlighted in ongoing investigations, likely contributed to selling pressure and uncertainty.
• The convergence of these factors is believed to have influenced the bearish market activity in TNDM stock today.

10.01.2026 - TNDM Stock was up 5.5%

• The bullish movement in TNDM stock today could be attributed to renewed investor interest following a recent decline and assessment of the company's valuation.
• Despite facing challenges such as the recent voluntary medical device correction for select insulin pumps, investors seem optimistic about Tandem Diabetes Care's future revenue growth and margin expansion potential.
• Analysis suggesting a near-term neutral sentiment might have also contributed to the stock's bullish movement, indicating a potential pause in the previous weakness and presenting favorable risk-reward setups for traders.